Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies

 
• By Jessica Merrill

As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.

Testing the drug on the basis of stem cell

More from Drug Pricing

More from Scrip